Emerson A. Lim

Comprehensive list of clinically relevant drugs screened in cell lines (not all were available at time of study). The list is divided into three sections, including one with FDA approved antineoplastics, one with experimental antineoplastics in clinical trials, and one with non-antineoplastics and tool compounds selectively screened when demonstrating an EC50 < 2μM.

Supplementary Figures S1-S6 and figure legends.

Detailed summary of drugs prioritized for testing in PDX models, based on rank of OncoTarget and OncoTreat predictions by –log10(Bonferroni p).

Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.

Curated list of proteins with high-affinity inhibitor drugs for OncoTarget analysis.

Detailed summary of therapeutic response at end-of-study time point, organized by study group—OncoTreat, OncoTarget, or Negative control—and then stratified by each individual drug arm. The study was underpowered for statistical analyses of therapeutic response in individual drug arms.

Prioritized drugs, prediction basis, and dosing schedule for PDX therapeutic study.

List of available interactomes (gene regulatory networks) that have been generated from RNASeq datasets of patient tumor samples using the ARACNe algorithm.

Current list of cancer cell lines with available drug perturbation RNASeq profiles, which together comprise the PanACEA resource.